Rapport Therapeutics (RAPP) Competitors $12.10 -1.06 (-8.05%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$12.10 0.00 (0.00%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RAPP vs. ANIP, MESO, OCUL, BGM, GPCR, AMPH, CALT, AUPH, CVAC, and MLYSShould you be buying Rapport Therapeutics stock or one of its competitors? The main competitors of Rapport Therapeutics include ANI Pharmaceuticals (ANIP), Mesoblast (MESO), Ocular Therapeutix (OCUL), Qilian International Holding Group (BGM), Structure Therapeutics (GPCR), Amphastar Pharmaceuticals (AMPH), Calliditas Therapeutics AB (publ) (CALT), Aurinia Pharmaceuticals (AUPH), CureVac (CVAC), and Mineralys Therapeutics (MLYS). These companies are all part of the "pharmaceutical products" industry. Rapport Therapeutics vs. Its Competitors ANI Pharmaceuticals Mesoblast Ocular Therapeutix Qilian International Holding Group Structure Therapeutics Amphastar Pharmaceuticals Calliditas Therapeutics AB (publ) Aurinia Pharmaceuticals CureVac Mineralys Therapeutics Rapport Therapeutics (NASDAQ:RAPP) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, community ranking, profitability, media sentiment and institutional ownership. Does the MarketBeat Community prefer RAPP or ANIP? ANI Pharmaceuticals received 438 more outperform votes than Rapport Therapeutics when rated by MarketBeat users. However, 75.00% of users gave Rapport Therapeutics an outperform vote while only 64.19% of users gave ANI Pharmaceuticals an outperform vote. CompanyUnderperformOutperformRapport TherapeuticsOutperform Votes375.00% Underperform Votes125.00% ANI PharmaceuticalsOutperform Votes44164.19% Underperform Votes24635.81% Do insiders and institutionals hold more shares of RAPP or ANIP? 76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 12.7% of ANI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is RAPP or ANIP more profitable? Rapport Therapeutics has a net margin of 0.00% compared to ANI Pharmaceuticals' net margin of -1.28%. ANI Pharmaceuticals' return on equity of 15.87% beat Rapport Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Rapport TherapeuticsN/A N/A N/A ANI Pharmaceuticals -1.28%15.87%6.88% Does the media favor RAPP or ANIP? In the previous week, ANI Pharmaceuticals had 4 more articles in the media than Rapport Therapeutics. MarketBeat recorded 6 mentions for ANI Pharmaceuticals and 2 mentions for Rapport Therapeutics. ANI Pharmaceuticals' average media sentiment score of 1.58 beat Rapport Therapeutics' score of 1.10 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapport Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ANI Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts recommend RAPP or ANIP? Rapport Therapeutics currently has a consensus price target of $32.67, suggesting a potential upside of 169.97%. ANI Pharmaceuticals has a consensus price target of $80.13, suggesting a potential upside of 27.63%. Given Rapport Therapeutics' higher possible upside, analysts plainly believe Rapport Therapeutics is more favorable than ANI Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rapport Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00ANI Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has stronger earnings & valuation, RAPP or ANIP? ANI Pharmaceuticals has higher revenue and earnings than Rapport Therapeutics. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRapport TherapeuticsN/AN/A-$34.79M-$3.45-3.51ANI Pharmaceuticals$674.07M2.02$18.78M-$1.27-49.43 SummaryANI Pharmaceuticals beats Rapport Therapeutics on 12 of the 16 factors compared between the two stocks. Get Rapport Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RAPP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RAPP vs. The Competition Export to ExcelMetricRapport TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$441.63M$6.85B$5.57B$8.63BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-3.518.7827.1320.06Price / SalesN/A255.64412.28157.10Price / CashN/A65.8538.2534.64Price / BookN/A6.557.064.70Net Income-$34.79M$143.93M$3.23B$247.88M7 Day Performance-1.87%3.84%2.86%2.63%1 Month Performance15.57%11.20%9.05%6.36%1 Year PerformanceN/A4.18%31.39%14.05% Rapport Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RAPPRapport Therapeutics1.7653 of 5 stars$12.10-8.1%$32.67+170.0%N/A$441.63MN/A-3.51N/APositive NewsANIPANI Pharmaceuticals4.2288 of 5 stars$61.91+5.4%$80.13+29.4%-3.3%$1.34B$674.07M-112.56600High Trading VolumeMESOMesoblast2.3496 of 5 stars$10.38-2.4%$18.00+73.4%+62.8%$1.33B$5.67M0.0080News CoverageAnalyst RevisionOCULOcular Therapeutix3.8423 of 5 stars$8.11+1.2%$16.25+100.4%+75.7%$1.29B$59.65M-6.14230Positive NewsBGMQilian International Holding GroupN/A$12.90-3.7%N/AN/A$1.25B$25.10M0.00298Positive NewsGap UpGPCRStructure Therapeutics2.5 of 5 stars$21.79+0.1%$79.86+266.5%-54.6%$1.25BN/A-29.45136News CoveragePositive NewsAnalyst RevisionAMPHAmphastar Pharmaceuticals3.6678 of 5 stars$25.38-1.3%$32.33+27.4%-36.7%$1.20B$730.66M8.461,620CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180AUPHAurinia Pharmaceuticals3.3372 of 5 stars$7.96+1.5%$11.50+44.5%+45.8%$1.08B$247.30M-53.06300Positive NewsAnalyst RevisionCVACCureVac4.4171 of 5 stars$4.63+3.6%$11.00+137.6%-4.2%$1.04B$523.70M8.42880Positive NewsMLYSMineralys Therapeutics3.3374 of 5 stars$15.70+0.8%$38.00+142.0%+19.7%$1.02BN/A-4.3128Positive NewsAnalyst Forecast Related Companies and Tools Related Companies ANIP Competitors MESO Competitors OCUL Competitors BGM Competitors GPCR Competitors AMPH Competitors CALT Competitors AUPH Competitors CVAC Competitors MLYS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RAPP) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapport Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapport Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RAPP Stock Free RAPP Stock Alerts